GSK reports Jemperli monotherapy shows 76% complete response in Phase II AZUR-1 rectal cancer trial

GSK reported that Jemperli (dostarlimab) monotherapy showed generally consistent safety in the Phase II AZUR-1 trial in MSI-H/dMMR rectal cancer, with serious adverse reactions in 20% of patients, discontinuations in 3%, and a 76% complete response rate.

Detected & updated continuously · Source: Nebula